How to Audit Your Audit Risks and Legal Exposure Management Process Before Inspectors Do

In the pharmaceutical and biotech sectors, compliance with regulations governing controlled substances is critical. Every company within this landscape must manage audit risks and legal exposure effectively. Understanding the regulatory requirements, implementation strategies, and compliance processes ensures that organizations remain well-prepared for inspections by regulatory authorities such as the FDA, EMA, and MHRA.

Context

Regulatory Affairs (RA) serves as the bridge between pharmaceutical companies and regulatory authorities, ensuring that products meet legal standards for safety, efficacy, and quality. A significant aspect of this function involves the management of audit risks and legal exposure, specifically regarding controlled substances. Given the complexities surrounding legal classification in different jurisdictions, organizations must adopt a proactive approach in auditing their compliance processes.

Legal/Regulatory Basis

The regulatory framework governing controlled substances primarily stems from various legislative acts and guidelines from regulatory authorities. Key regulations include:

• 21 CFR Part 1300 – 1399 (Controlled Substances Act): This outlines the scheduling of controlled substances in the US, including definitions and classifications.
• EU Regulation (EC) No 726/2004: This regulation governs the authorization of medicinal products, including provisions for controlled substances in the EU.
• UK Misuse of Drugs Act 1971: Governs the control of substances that are classified as illegal drugs in the UK.
• ICH Guidelines: Offers a framework for the development and registration of pharmaceuticals across different regions, emphasizing harmonized clinical data and compliance.

The legal classification of substances is crucial for determining the applicable regulatory requirements. Understanding the different schedules and associated regulations is fundamental for compliance.

Documentation

Effective audit risks and legal exposure management begins with comprehensive documentation. Key documents should include:

• Controlled Substance Inventory logs: Detailed logs must be maintained reflecting quantities on hand, usage, and disposal.
• Ordering Records: Documentation of all orders for controlled substances, including supplier data and receipts.
• Compliance Training Records: Evidence of employee training on legal classifications and proper handling of controlled substances.
• Standard Operating Procedures (SOPs): Well-defined SOPs for the management of controlled substances that align with regulatory expectations.
• Internal Audit Reports: Regular internal audits should be documented to evaluate compliance with controlled substances regulations.

These documents provide evidence of compliance when responding to regulatory authorities during inspections and serve as internal checks to identify gaps or weaknesses in the compliance framework.

Review/Approval Flow

The review and approval flow for documentation concerning controlled substances typically follows a structured process:

1. Preparation of Documents: Preparation of all necessary compliance documents includes inventory management logs and training records.
2. Internal Review: A designated internal compliance team should review the prepared documents for accuracy and completeness.
3. Sign-off by Quality Assurance (QA): QA should provide final approval on documents before submission to ensure alignment with internal policies and regulatory compliance.
4. Submission to Regulatory Authorities: Maintain a record of all submitted documents and communications with regulatory bodies.
5. Follow-up and Responses: Any feedback from the regulatory authority should be documented and acted upon promptly.

Common Deficiencies

Regulatory inspections often reveal recurring deficiencies regarding audit risks and legal exposure management. Key areas of concern include:

• Incomplete Documentation: Inadequate records regarding controlled substances can lead to significant compliance issues.
• Lack of Training: Failing to actively train staff on controlled substance regulations contributes to non-compliance.
• Inadequate SOPs: SOPs that are not clear or up-to-date can create confusion and increase the risk of non-compliance.
• Failure to Address Previous Audit Findings: Not implementing corrective actions based on prior audit findings increases the risk of audit failures.

To avoid frequent pitfalls, organizations must conduct regular self-audits and ensure continuous training and updates to compliance documentation.

RA-Specific Decision Points

Throughout compliance and regulatory processes, certain decision points are critical for managing audit risks and ensuring legal exposure is minimized:

When to File as Variation vs. New Application

In cases where changes occur in the handling or classification of a controlled substance, determining if it necessitates a variation or if a new application is needed is essential:

• Filing as a Variation: If the changes are minor, such as adjustments to inventory management practices without affecting the central regulatory obligations, a variation may be appropriate.
• Filing as a New Application: If there are significant changes in the formulation, route of administration, or intended use of a controlled substance, a completely new application may be required to ensure comprehensive evaluation by regulatory authorities.

How to Justify Bridging Data

In some instances, organizations may need to utilize bridging data to support a regulatory submission:

• Identify Relevant Data: Conduct a thorough review of existing data from similar substances or previous studies and identify relevant aspects that can bridge the current application.
• Data Integrity and Relevance: It is crucial to ensure that the bridging data is robust, valid, and applicable to the current submission, addressing any potential concerns raised by the regulatory agency.
• Comprehensive Justification: Provide a detailed justification of why bridging data is appropriate and how it supports meeting the regulatory requirements.

Inspection Readiness

Organizations must adopt a culture of inspection readiness, which involves ongoing assessments and real-time compliance tracking. Key steps include:

• Conducting Mock Inspections: Regular mock inspections help familiarize staff with the actual process and highlight areas requiring improvement.
• Continuous Monitoring: Implement monitoring systems that track compliance metrics and detect deviations before they escalate.
• Engagement with Regulatory Authorities: Maintain open communication lines with regulators to address any questions beforehand and clarify guidelines.

Inspection readiness is not merely about having the required documents in place. It also involves a comprehensive understanding of regulations and a continuous commitment to maintaining compliance across all levels.

Practical Tips for Documentation, Justifications, and Responses to Agency Queries

To ensure effective management of audit risks and legal exposure, implement practical strategies in documentation, justifications, and responses:

Documentation Tips

• Consistent Formats: Use standard formats for all documentation to facilitate reviews and audits.
• Accurate and Timely Updates: Regularly update documentation to reflect changes in procedures, regulations, or inventory.
• Cross-Verification: Have multiple personnel cross-check documentation to minimize errors.

Justifications Tips

• Data-Driven Justifications: Rely on quantitative data to support any changes or submissions made.
• Clear Rationale: Provide clear and logical explanations for any decisions made regarding controlled substances.

Responding to Agency Queries

• Timely Responses: Promptly address any queries from regulatory agencies with complete and accurate information.
• Documented Communications: Keep records of all communications with regulatory authorities.
• Request Clarifications When Needed: If any query from the agency is unclear, do not hesitate to ask for further clarification.

Conclusion

Effectively auditing audit risks and managing legal exposure in the field of controlled substances compliance requires a comprehensive understanding of the relevant regulations and guidelines, meticulous documentation, and a culture of compliance within organizations. By implementing structured review processes, training systems, and proactive compliance management, pharmaceutical and biotech companies can minimize regulatory risk and navigate audit processes successfully.

Ensuring every aspect of compliance is diligently monitored not only prepares organizations for inspections but also solidifies their reputation and reliability within the industry.